Citigroup Inc Ocuphire Pharma, Inc. Transaction History
Citigroup Inc
- $153 Billion
- Q2 2024
Shares
2 transactions
Others Institutions Holding OCUP
# of Institutions
42Shares Held
2.74MCall Options Held
2KPut Options Held
2K-
Vanguard Group Inc Valley Forge, PA992KShares$1.28 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA266KShares$342,9510.0% of portfolio
-
Rice Hall James & Associates, LLC224KShares$288,4290.02% of portfolio
-
Richmond Brothers, Inc. Jackson, MI191KShares$246,7820.6% of portfolio
-
Bridgeway Capital Management, LLC Houston, TX164KShares$211,2250.01% of portfolio
About Ocuphire Pharma, Inc.
- Ticker OCUP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 20,579,800
- Market Cap $26.5M
- Description
- Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Its lead product candidate is Nyxol eye drops, a once-daily preservative-free eye drop formulation of phentolamine mesylate, which is in Phase III clinical tr...